Literature DB >> 12117960

Structure-function analysis of decay-accelerating factor: identification of residues important for binding of the Escherichia coli Dr adhesin and complement regulation.

Rafia J Hasan1, Edyta Pawelczyk, Petri T Urvil, Mathura S Venkatarajan, Pawel Goluszko, Jozef Kur, Rangaraj Selvarangan, Stella Nowicki, Werner A Braun, Bogdan J Nowicki.   

Abstract

Decay-accelerating factor (DAF), a complement regulatory protein, also serves as a receptor for Dr adhesin-bearing Escherichia coli. The repeat three of DAF was shown to be important in Dr adhesin binding and complement regulation. However, Dr adhesins do not bind to red blood cells with the rare polymorphism of DAF, designated Dr(a(-)); these cells contain a point mutation (Ser165-Leu) in DAF repeat three. In addition, monoclonal antibody IH4 specific against repeat three was shown to block both Dr adhesin binding and complement regulatory functions of DAF. Therefore, to identify residues important in binding of Dr adhesin and IH4 and in regulating complement, we mutated 11 amino acids-predominantly those in close proximity to Ser165 to alanine-and expressed these mutations in Chinese hamster ovary cells. To map the mutations, we built a homology model of repeat three based on the poxvirus complement inhibitory protein, using the EXDIS, DIAMOD, and FANTOM programs. We show that perhaps Ser155, and not Ser165, is the key amino acid that interacts with the Dr adhesin and amino acids Gly159, Tyr160, and Leu162 and also aids in binding Dr adhesin. The IH4 binding epitope contains residues Phe148, Ser155, and L171. Residues Phe123 and Phe148 at the interface of repeat 2-3, and also Phe154 in the repeat three cavity, were important for complement regulation. Our results show that residues affecting the tested functions are located on the same loop (148 to 171), at the same surface of repeat three, and that the Dr adhesin-binding and complement regulatory epitopes of DAF appear to be distinct and are approximately 20 A apart.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117960      PMCID: PMC128121          DOI: 10.1128/IAI.70.8.4485-4493.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.

Authors:  N A Clarkson; R Kaufman; D M Lublin; T Ward; P A Pipkin; P D Minor; D J Evans; J W Almond
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

2.  Characterization of the active sites in decay-accelerating factor.

Authors:  L A Kuttner-Kondo; L Mitchell; D E Hourcade; M E Medof
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

3.  Studies on C3 convertases. Inhibition of C5 convertase formation by peptides containing aromatic amino acids.

Authors:  A Kossorotow; W Opitz; E Etschenberg; U Hadding
Journal:  Biochem J       Date:  1977-11-01       Impact factor: 3.857

4.  Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.

Authors:  K E Coyne; S E Hall; S Thompson; M A Arce; T Kinoshita; T Fujita; D J Anstee; W Rosse; D M Lublin
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

Review 5.  Blood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteins.

Authors:  G Garratty
Journal:  Immunol Invest       Date:  1995 Jan-Feb       Impact factor: 3.657

6.  Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.

Authors:  K Iwata; T Seya; H Ariga; S Nagasawa
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

7.  dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor.

Authors:  T Pham; A Kaul; A Hart; P Goluszko; J Moulds; S Nowicki; D M Lublin; B J Nowicki
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).

Authors:  J M Bergelson; J G Mohanty; R L Crowell; N F St John; D M Lublin; R W Finberg
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction.

Authors:  B Nowicki; A Hart; K E Coyne; D M Lublin; S Nowicki
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  15 in total

1.  Role of Src kinases in mobilization of glycosylphosphatidylinositol-anchored decay-accelerating factor by Dr fimbria-positive adhering bacteria.

Authors:  Christophe J Queval; Valérie Nicolas; Isabelle Beau
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

2.  A multimeric model for murine anti-apoptotic protein Bcl-2 and structural insights for its regulation by post-translational modification.

Authors:  Venkatarajan S Mathura; Kizhake V Soman; Tushar K Varma; Werner Braun
Journal:  J Mol Model       Date:  2003-08-30       Impact factor: 1.810

3.  Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.

Authors:  Sompong Vongpunsawad; Numan Oezgun; Werner Braun; Roberto Cattaneo
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  Hydrophilic domain II of Escherichia coli Dr fimbriae facilitates cell invasion.

Authors:  Margaret Das; Audrey Hart-Van Tassell; Petri T Urvil; Susan Lea; David Pettigrew; K L Anderson; Alfred Samet; Jozef Kur; Steve Matthews; Stella Nowicki; Vsevolod Popov; Pawel Goluszko; Bogdan J Nowicki
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 5.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 6.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Complement protective epitopes and CD55-microtubule complexes facilitate the invasion and intracellular persistence of uropathogenic Escherichia coli.

Authors:  Tanu Rana; Rafia J Hasan; Stella Nowicki; Mathura S Venkatarajan; Rajbir Singh; Petri T Urvil; Vsevolod Popov; Werner A Braun; Waldemar Popik; J Shawn Goodwin; Bogdan J Nowicki
Journal:  J Infect Dis       Date:  2013-11-20       Impact factor: 5.226

8.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Chimeric Dr fimbriae with a herpes simplex virus type 1 epitope as a model for a recombinant vaccine.

Authors:  Beata Zalewska; Rafał Piatek; Grazyna Konopa; Bogdan Nowicki; Stella Nowicki; Józef Kur
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Preterm labor: CD55 in maternal blood leukocytes.

Authors:  Stella Nowicki; Michael G Izban; Edyta Pawelczyk; Vincent K Agboto; Siddarth Pratap; Gayle Olson; Bogdan Nowicki
Journal:  Am J Reprod Immunol       Date:  2009-05       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.